Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Impact Of Cdkn2a Gene Expression On Colon Adenocarcinoma Via Biosignature Analysis

Impact of CDKN2A gene expression on colon adenocarcinoma via biosignature analysis

Chen Xu1

  • 13201 Hospital, Han Zhong, Shaanxi, China.

Medicine
|September 10, 2024

Related Experiment Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

6.9K

View abstract on PubMed

Summary
This summary is machine-generated.

Cyclin-dependent kinase inhibitor 2A (CDKN2A) is highly expressed in colorectal adenocarcinoma, correlating with shorter survival and altered immune cell infiltration. This suggests CDKN2A is a poor prognostic marker for COAD.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Colorectal adenocarcinoma (COAD) presents a significant clinical challenge with a poor prognosis.
  • The role of Cyclin-dependent kinase inhibitor 2A (CDKN2A) in COAD pathogenesis and progression requires further elucidation.
  • Understanding CDKN2A's molecular mechanisms is crucial for identifying novel therapeutic targets.

Purpose of the Study:

  • To investigate the expression levels, clinical significance, and biological functions of CDKN2A in COAD.
  • To explore the correlation between CDKN2A expression and immune cell infiltration in COAD.
  • To identify potential pathways regulated by CDKN2A in colorectal adenocarcinoma.

Main Methods:

  • Utilized multiple public databases (e.g., UAB Cancer Data Analysis Portal, GEPIA, TIMER, Human Protein Atlas, STRING, GeneMANIA, cBioPortal, Linked Omics) for comprehensive analysis.

Related Experiment Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

6.9K
  • Assessed CDKN2A expression levels, clinical correlations, co-expressed genes, and pathway enrichment.
  • Analyzed immune cell infiltration and genomic mutation data related to CDKN2A in COAD.

    • Main Results:

    • CDKN2A exhibited significantly higher expression in colon adenocarcinomas compared to normal tissues (P < .001).
    • Elevated CDKN2A expression was associated with shorter patient survival (P = .011) and altered immune cell infiltration (positive correlation with CD4+ T cells, macrophages, neutrophils; negative with B cells).
    • Gene Ontology and KEGG analyses revealed enrichment in apoptotic and metabolic pathways; CDKN2A mutations were linked to reduced survival.

    Conclusions:

    • CDKN2A serves as a valuable biomarker for predicting poor prognosis in colorectal adenocarcinoma patients.
    • CDKN2A may influence COAD development and progression by modulating immune cell infiltration and metabolic pathways.
    • Further research into CDKN2A's role could uncover new therapeutic strategies for COAD.